Human KLF6 Antibody

Detection of KLF6 by Western Blot

miR-630 targeted KLF6. (A) Target genes of miR-630 were predicted through TargetScan7, RNAInter (Score > 0.70), and miRDB (Score > 70) databases; (B) binding site between miR-630 and KLF6 was predicted through databases; (C) targeting relationship between miR-630 and KLF6 was verified using dual-luciferase reporter gene assay; (D) RIP assay verified the interaction between miR-630 and KLF6 mRNA; (E,F) KLF6 expression in cells in each group was detected using RT-qPCR and Western blotting; (G–J) KLF6 expression in NFs after different treatments was detected using RT-qPCR and Western blotting. The experiment was repeated three times independently. Data are presented as mean ± standard deviation. Data in panel (C–F) were analyzed using t-test, and data in panels (G–J) were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison test, **p < 0.01, ***p < 0.001. A2780 and SKOV3 in panels (I,J) indicated the source of EVs. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34277601), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of KLF6 by Western Blot

Overexpression of KLF6 attenuated EVs-induced activation of CAFs. NFs were co-treated with A2780 or SKOV3 cells-derived EVs and KLF6 pcDNA or its NC. (A,B) Transfection efficiency of KLF6 pcDNA was confirmed using RT-qPCR and Western blotting; (C,D) levels of CAFs marker proteins ( alpha -SMA and FAP) in NFs were detected using RT-qPCR and Western blotting. (E) Migration of NFs in each group was detected using Transwell assay; the migrated cells were counted and representative images were displayed. The experiment was repeated three times independently. Data are presented as mean ± standard deviation and analyzed using one-way ANOVA, followed by Tukey’s multiple comparison test, **p < 0.01, ***p < 0.001. A2780 and SKOV3 in the panels (C,D) indicated the source of EVs. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34277601), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of KLF6 by Western Blot

miR-630 targeted KLF6. (A) Target genes of miR-630 were predicted through TargetScan7, RNAInter (Score > 0.70), and miRDB (Score > 70) databases; (B) binding site between miR-630 and KLF6 was predicted through databases; (C) targeting relationship between miR-630 and KLF6 was verified using dual-luciferase reporter gene assay; (D) RIP assay verified the interaction between miR-630 and KLF6 mRNA; (E,F) KLF6 expression in cells in each group was detected using RT-qPCR and Western blotting; (G–J) KLF6 expression in NFs after different treatments was detected using RT-qPCR and Western blotting. The experiment was repeated three times independently. Data are presented as mean ± standard deviation. Data in panel (C–F) were analyzed using t-test, and data in panels (G–J) were analyzed using one-way ANOVA, followed by Tukey’s multiple comparison test, **p < 0.01, ***p < 0.001. A2780 and SKOV3 in panels (I,J) indicated the source of EVs. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/34277601), licensed under a CC-BY license. Not internally tested by R&D Systems.